Mitomycin C Treatment for Conjunctival—Corneal Intraepithelial Neoplasia: A Multicenter Experience
References (23)
- et al.
Conjunctival and corneal intraepithelial and invasive neoplasia
Ophthalmology
(1986) - et al.
Clinical and pathologic description of 17 cases of corneal intraepithelial neoplasia
Am J Ophthalmol
(1984) - et al.
Management of intraepithelial conjunctival tumors and squamous cell carcinomas
Am J Ophthalmol
(1983) - et al.
The use of strontium-90 in the treatment of carcinoma in situ of the conjunctiva
Am J Ophthalmol
(1979) - et al.
Mitomycin eye drops as treatment for pterygium
Ophthalmology
(1988) - et al.
Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium
Am J Ophthalmol
(1988) Mitomycin as adjunct chemotherapy with trabeculectomy
Ophthalmology
(1991)- et al.
Mitomycin C therapy for corneal intraepithelial neoplasia
Am J Ophthalmol
(1994) - et al.
Intraoperative application of topical mitomycin C for pterygium surgery
Ophthalmology
(1996) - et al.
The use of low dose mitomycin C for prevention of recurrent pterygium
Ophthalmology
(1994)
Cited by (169)
Personalized treatment concepts in extraocular cancer
2024, Advances in Ophthalmology Practice and ResearchTopical 5-fluorouracil 1% for moderate to extensive ocular surface squamous neoplasia in 73 consecutive patients: Primary versus secondary treatment
2024, Asia-Pacific Journal of OphthalmologyEffects of corneal epithelial superficial keratectomy in patients with focal limbal stem cell disease
2022, American Journal of Ophthalmology Case ReportsCitation Excerpt :These severe cases are a contra-indication for our technique. According to the principle of starting with the least invasive treatment, topical eye drops such as mitomycin C25 should have been performed first, but we did not try mitomycin C prior to keratectomy because there was a report that its use can, in fact, induce LSC disorder.26 A further limitation is that long-term survival has not been assured, as the longest follow-up period was 3 years (Case 2).
Canalicular Stenosis Secondary to Chemotherapeutic Agents
2021, Advances in Ophthalmology and OptometryCitation Excerpt :MMC is a chemotherapeutic antibiotic that cross-links DNA base pairs adenine and guanine, inhibiting the synthesis of DNA. It has been used to treat several ocular conditions, including conjunctival corneal intraepithelial neoplasia [17], primary acquired melanoma [18], as well as glaucoma [19] and pterygium surgeries [3]. Punctal-canalicular stenosis secondary to MMC was first described in 2003 in a case report of a 62-year-old woman who was treated with MMC for corneal epithelial dysplasia [20].
Ocular surface complications of local anticancer drugs for treatment of ocular tumors
2021, Ocular SurfaceCitation Excerpt :Superficial keratitis is often observed in eyes treated with local anticancer drugs, and can be attributed to increased inflammatory response induced by drugs, such as IFN-α and imiquimod, that act by boosting the immune system [58,61,70,71,123–125]. Contact dermatitis and allergic lid reaction including edema, blepharitis, ectropion, erythema, eyelid inflammation and blepharospasm have been reported in eyes administered topical MMC (10–34%) [16,20,21,24,26,27] and topical 5-FU (5–49.2%) [34,37–40,43,44]. Punctal and canalicular obstruction leading to epiphora are well-known complications associated with many systemic chemotherapies.
Presented as a paper at the American Academy of Ophthalmology Annual Meeting, Chicago, October 1996.
The authors have no proprietary interest in the development or marketing of this or a competing drug.